While immune checkpoint inhibitors are promising next-generation therapies, response rates remain limited to 10–30%, leaving many patients without benefit. Consequently, neoantigen-based cancer vaccines capable of inducing patient-specific immune responses have emerged as a vital alternative.
However, the difficulty in accurate and rapid prediction of immunogenic T cell epitopes has left many cancer vaccine developers at the early R&D stage. NEO-ARS® technology addresses this bottleneck through AI-based 3D structural analysis and T cell reactivity prediction.
NEO-ARS® is an AI-driven platform that rapidly and precisely identifies tumor-specific neoantigens. Leveraging patient-derived genomic data, it analyzes tumor-specific mutations and predicts their potential to be recognized by immune cells (T cells).
By automating complex processes—from NGS-based variant analysis to peptide–MHC binding prediction and immunogenicity simulation—into a single AI pipeline, it rapidly predicts personalized neoantigen targets that are difficult to identify with conventional methods. This enables enhanced precision in target antigen selection and accelerated development in the cancer vaccine and T cell therapy fields.
NEO-ARS® is an AI-driven cancer immunotherapy design platform that identifies neoantigens (tumor-specific antigens, TSAs) by covering the whole process, from NGS data analysis to structure-based prediction of HLA class I-restricted immunogenic T cell epitopes using multiple algorithms.
In particular, the ex vivo data we have already obtained through prospective studies with several clinicians regarding the prediction-validation of 'personalized neoantigens' provides strong evidence of therapeutic potential and establishes our leadership in next-generation cancer immunotherapy.
※ Compared to TAAs, neoantigens show stronger immunogenicity. Highly immunogenic TSAs provide better targets for personalized cancer immunotherapy, as they can induce a robust T-cell response without significant off-target effects on healthy tissues.
※ TCR-engineered T cell (TCR-T) therapy represents the next-generation approach for treating hematologic malignancies. Just as in cancer vaccine development for solid tumors, our AI platform's ability to accurately and rapidly predict neoantigens can dramatically accelerate development of adoptive T cell transfer therapy.
